Do we have evidence for policy changes in the treatment of children with latent tuberculosis infection?

Pediatrics

Volumn 123, Issue 3, 2009, Pages 902-903

  Lobato, Mark N ^a   Jereb, John A ^a,b   Castro, Kenneth G ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HEALTH PROGRAM; HEPATITIS; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NOTE; PRIORITY JOURNAL; SILICOSIS; TREATMENT RESPONSE; TUBERCULOSIS; CHILD; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMICS; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; STATISTICS;

ANTITUBERCULAR AGENTS; CHILD; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; EVIDENCE-BASED MEDICINE; HEALTH POLICY; HUMANS; ISONIAZID; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 63149145073     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-2664     Document Type: Note

References (17)

1. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res. 1970;17:28-106
2. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis. 1962;85:490-510
3. Advisory Council for the Elimination of Tuberculosis. Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment. MMWR Recomm Rep. 1999;48(RR-9):1-13
4. Bennett DE, Courval JM, Onorato I, et al. Prevalence of tuberculosis infection in the United States population. Am J Respir Crit Care Med. 2008;177(3):348-355
5. Finnell SME, Christenson JC, Downs SM. Latent tuberculosis infection in children: a call for revised treatment guidelines. Pediatrics. 2009;123(3):816-822
6. Comstock GW, Woolpert SH. Prophylaxis. In: David Schloss-berg, ed. Tuberculosis. 2nd ed. New York, NY: Springer; 1998:55-59
7. Comstock GW, Baum C, Snider DE. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies. Am Rev Respir Dis. 1979;119(5):827-830
8. Curry FJ. Prophylactic effect of isoniazid in young tuberculin reactors. N Engl J Med. 1967;277(11):562-567
9. Hsu K. Thirty years after isoniazid: it's impact on tuberculosis in children and adolescents. JAMA. 1984;251(10):1283-1285
10. Hong Kong Chest Service, Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemo-prophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis. 1992;145(1):36-41
11. World Health Organization. Anti-tuberculosis Drug Resistance in the World: Fourth Global Report. Geneva, Switzerland: World Health Organization; 2008. WHO/HTM/TB/2008.394
12. Pediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents. Pediatrics. 2004;114(4 suppl):1175-1201
13. Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child. 1998;78(2):169-171
14. Ena J, Valls V. Short-course therapy with rifampin plus isoni-azid compared with standard therapy with isoniazid for latent tuberculosis infection: a meta-analysis. Clin Infect Dis. 2005;40(5):670-676
15. Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazin-amide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA. 2000;283(11):1445-1450
16. McElroy PD, Ijaz K, Lambert LA, et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection [published correction appears in Clin Infect Dis. 2006; 42(2):313]. Clin Infect Dis. 2005;41(8):1125-1133
17. Khan K, Muennig P, Behta M, Zivin J. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med. 2002;347(23):1850-1859